PinkDx raises $5 million

PinkDx has raised an additional $5 million in its Series A financing round, bringing the total to $45 million. The funding, led by Catalio Capital Management, The Production Board, and Mountain Group Partners, with new investors including Blue Venture Fund , Sandbox Clinical Ventures, and BEVC.

Founded in 2021, PinkDx will initially focus on improving the diagnostic outcomes for women who have vague symptoms that may signal a gynecological cancer.

“We are delighted to welcome these new investors as they each offer strategic value that will be helpful as we develop and advance our first test toward commercialization. We are making great progress in the discovery and development of our first test and this additional funding will help accelerate that process through the test’s clinical validation.” – Bonnie Anderson, PinkDx’s cofounder, chairwoman and chief executive officer.